Electronic cigarette (e-cigarette) use continues to grow with most users reporting concurrent cigarette smoking, but few studies have focused on tobacco use and toxicant exposure among naturalistic dual-using populations. This controlled clinical laboratory study examined how dual versus exclusive use of e-cigarettes and cigarettes and no tobacco/nicotine affected behavioral, physiological, and subjective measures among current dual users. Twenty-two participants identifying as cigarette (≥ 10 cigarettes per day [CPD]) and e-cigarette (≥ 3 days/week) users of "cig-a-like" e-cigarettes completed four 5-day outpatient conditions, which differed by their own brand of products used ad libitum: (a) cigarette and e-cigarette (dual), (b) cigarette-only, (c) e-cigarette-only, and (d) no tobacco/nicotine. Primary outcomes included daily tobacco use, expired air carbon monoxide (CO), and urinary cotinine and NNAL. Linear mixed models with pairwise comparisons (Bonferroni corrected) were performed (p < .05). CPD did not differ significantly between dual and cigarette-only use, but e-cigarette use and liquid consumed increased significantly during e-cigarette-only relative to dual use. Relative to dual use, expired air CO did not differ during cigarette-only and was significantly lower during e-cigarette-only use. Urinary cotinine was significantly lower during e-cigarette-only use relative to dual and cigarette-only use, while urinary NNAL did not differ between the nicotine-containing conditions. In summary, among current dual users, e-cigarettes in combination with cigarettes did not reduce CPD relative to exclusive cigarette use or toxicant exposure relative to exclusive use of either product. However, exclusive e-cigarette use did reduce CO and cotinine, highlighting the benefits of cigarette cessation. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307076 | PMC |
http://dx.doi.org/10.1037/pha0000417 | DOI Listing |
JAMA Ophthalmol
January 2025
John A. Moran Eye Center, Department of Ophthalmology & Visual Sciences, Department of Neurology, University of Utah Health, Salt Lake City.
Importance: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications.
Objective: To report ophthalmic complications associated with the use of semaglutide or tirzepatide.
Environ Sci Technol
January 2025
MOE Key Laboratory of Groundwater Quality and Health, School of Environmental Studies, China University of Geosciences, Wuhan 430078, China.
Groundwater can be contaminated by PFAS emissions, yet research on the presence and associated risks of PFAS in groundwater underlying different land-use areas remains limited. Herein, high-resolution mass spectrometry-based suspect and nontarget analyses were performed to determine PFAS occurrence in groundwater samples obtained from a rural area, a planting region, and the vicinities of a pharmaceutical park, an airport, and an industrial park in Datong City, China. A total of 31 PFAS (16 emerging and 15 legacy PFAS) were identified, and the ΣPFAS concentrations ranged from 0.
View Article and Find Full Text PDFJ Occup Health
January 2025
Department of Environmental and Preventive Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke 329-0498Japan.
With the explosive development of nanotechnology, engineered nanomaterials are currently being used in various industries, including food and medicine. Concern about the health effects of nanomaterials has been raised, and available research indicates that the relative surface area of nanomaterials seems to correlate with the severity of their toxicity. With regard to engineered nanomaterials, the scope of their acute and chronic toxicities and their mechanisms are not fully understood.
View Article and Find Full Text PDFClin Toxicol (Phila)
January 2025
National Poisons Information Service, Cardiff Unit, University Hospital Llandough, Penarth, UK.
Introduction: Ibogaine is a psychoactive alkaloid derived from the root bark of the West African shrub . It is not licensed in the United Kingdom but is used by individuals to alleviate drug or alcohol use.
Methods: A retrospective analysis of telephone enquiries involving ibogaine between 1 January 2012 and 31 December 2022 to the United Kingdom National Poisons Information Service was performed.
Heliyon
January 2025
Department of Animal Production and Health, School of Agriculture and Agricultural Technology, Federal University of Technology,P. M. B. 704, Akure, Ondo State, Nigeria.
This research evaluated the profiling of bioactive compounds and insecticidal activities of the crude extracts of horns and hoofs of cow and goat against on wheat grains. Different concentrations (0.1, 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!